cam 2

Cam 2445 is a nonpeptide, alpha-methyltryptophan derivative; an NK1 neurokinin receptor antagonist that is a potentially useful treatment for arthritis, asthma, migraine, anxiety, psychosis, and emesis.

Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6 15 2 3 3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.

MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

W-9 hydrochloride is a calmodulin antagonist.

CaM kinase II inhibitor TFA salt (Autocamtide-2-related inhibitory peptide (TFA)) is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.

Autocamtide-2-related inhibitory peptide, myristoylated acetate is a CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide.

2-oxo Clopidogrel((±)-SR-121683)) is a drug metabolite and thiolactone intermediate of Clopidogrel, which is catalyzed by hepatic cytochrome P450 (P450) enzymes via CYP3A oxidation, and is capable of further post hydrolysis to the active metabolite CAM.Clopidogrel is an antithrombotic pro-drug.

STO-609 acetate is selective, cell-permeable inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki: 80 15 ng ml, for CaM-KKα KKβ); competes for the ATP-binding site. It displays > 80-fold selectivity over CaMK1 2 4, PKC, MLCK, PKA and p42 MAPK.

Calmodulin antagonist-1 (W-7) is a calmodulin (CaM) antagonist that effectively inhibits calmodulin-activated Ca 2+ -phosphodiesterase (PDE) with an IC 50 of 28 μM. This compound also competitively inhibits trypsin-treated Ca 2+ -PDE with respect to cyclic GMP, exhibiting an IC 50 of 375 μM and a K i value of 300 μM.

Syntide 2 (TFA), a substrate peptide for Ca2+- and calmodulin (CaM)-dependent protein kinase II (CaMKII), selectively inhibits the gibberellin (GA) response without affecting constitutive and abscisic acid-regulated events [1].

CALP2 TFA, a potent calmodulin (CaM) antagonist with a dissociation constant (Kd) of 7.9 µM, exhibits high affinity for the CaM EF-hand Ca2+-binding site. This compound effectively inhibits CaM-dependent phosphodiesterase activity and elevates intracellular Ca2+ concentrations. Furthermore, it significantly hinders adhesion and degranulation, while also acting as a robust activator of alveolar macrophages [1] [2] [3] [4].

CALP1 TFA, a calmodulin (CaM) agonist with a dissociation constant (Kd) of 88 µM, selectively binds to the CaM EF-hand Ca2+-binding site, inhibiting calcium channel opening. This action blocks calcium influx and apoptosis with an IC50 of 44.78 µM, modulates glutamate receptor channel activity, and impedes a store-operated nonselective cation channel. Additionally, CALP1 TFA enhances CaM-dependent phosphodiesterase activity, denoting its multifaceted role in modulating cellular calcium dynamics [1] [2] [3] [4].

Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide that interacts specifically with calmodulin-dependent protein kinases (CaMK) and requires calcium ions (Ca 2+) and calmodulin (CaM) for activation. It is utilized in studies involving protein kinase activity [1].

Syntide 2 (TFA) is a Ca2+ and CaM dependent protein kinase II (CaMKII) substrate peptide that selectively inhibits the gibberellin (GA) response, leaving composition and slicoic acid regulatory events unaffected.

CaMKI (299-320) is a peptide representing residues 299-320 of Calcium calmodulin-dependent protein kinase I (CaMKI). This segment, functioning as a protein kinase, exhibits a strong interaction with Ca 2+ -CAM (K d ≤1 nM), enabling it to phosphorylate specific substrate proteins and regulate their activity. It encompasses both the CAM-binding domain and the self-inhibition domain. CaMKI (299-320) is applicable for researching cellular physiological processes such as proliferation, differentiation, and apoptosis .